Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations

被引:701
作者
Pearson, Ewan R.
Flechtner, Isabelle
Njolstad, Pal R.
Malecki, Maciej T.
Flanagan, Sarah E.
Larkin, Brian
Ashcroft, Frances M.
Klimes, Iwar
Codner, Ethel
Iotova, Violeta
Slingerland, Annabelle S.
Shield, Julian
Robert, Jean-Jacques
Holst, Jens J.
Clark, Penny M.
Ellard, Sian
Sovik, Oddmund
Polak, Michel
Hattersley, Andrew T.
机构
[1] Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX2 5DW, Devon, England
[2] Univ Dundee, Div Med & Therapeut, Dundee, Scotland
[3] Univ Lab Physiol, Oxford, England
[4] Univ Bristol, Dept Child Hlth, Bristol, Avon, England
[5] Univ Hosp Birmingham, Birmingham, W Midlands, England
[6] Univ Paris 05, Fac Med, Hop Necker Enfants Malad, Paris, France
[7] Univ Bergen, Dept Clin Med, Bergen, Norway
[8] Haukeland Univ Hosp, Dept Pediat, N-5021 Bergen, Norway
[9] Jagiellonian Univ, Coll Med, Dept Metab Dis, Krakow, Poland
[10] Slovak Acad Sci, Inst Expt Endocrinol, Bratislava, Slovakia
[11] Univ Chile, Sch Med, Inst Maternal & Child Res, Santiago, Chile
[12] Med Univ, Varna, Bulgaria
[13] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands
[14] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark
基金
英国惠康基金;
关键词
D O I
10.1056/NEJMoa061759
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Heterozygous activating mutations in KCNJ11, encoding the Kir6.2 subunit of the ATP-sensitive potassium (K(sub ATP)) channel, cause 30 to 58 percent of cases of diabetes diagnosed in patients under six months of age. Patients present with ketoacidosis or severe hyperglycemia and are treated with insulin. Diabetes results from impaired insulin secretion caused by a failure of the beta-cell K(sub ATP) channel to close in response to increased intracellular ATP. Sulfonylureas close the K(sub ATP) channel by an ATP-independent route. METHODS: We assessed glycemic control in 49 consecutive patients with Kir6.2 mutations who received appropriate doses of sulfonylureas and, in smaller subgroups, investigated the insulin secretory responses to intravenous and oral glucose, a mixed meal, and glucagon. The response of mutant K(sub ATP) channels to the sulfonylurea tolbutamide was assayed in xenopus oocytes. RESULTS: A total of 44 patients (90 percent) successfully discontinued insulin after receiving sulfonylureas. The extent of the tolbutamide blockade of K(sub ATP) channels in vitro reflected the response seen in patients. Glycated hemoglobin levels improved in all patients who switched to sulfonylurea therapy (from 8.1 percent before treatment to 6.4 percent after 12 weeks of treatment, P<0.001). Improved glycemic control was sustained at one year. Sulfonylurea treatment increased insulin secretion, which was more highly stimulated by oral glucose or a mixed meal than by intravenous glucose. Exogenous glucagon increased insulin secretion only in the presence of sulfonylureas. CONCLUSIONS: Sulfonylurea therapy is safe in the short term for patients with diabetes caused by KCNJ11 mutations and is probably more effective than insulin therapy. This pharmacogenetic response to sulfonylureas may result from the closing of mutant K(sub ATP) channels, thereby increasing insulin secretion in response to incretins and glucose metabolism.
引用
收藏
页码:467 / 477
页数:11
相关论文
共 31 条
  • [1] Type 2 diabetes mellitus: not quite exciting enough?
    Ashcroft, F
    Rorsman, P
    [J]. HUMAN MOLECULAR GENETICS, 2004, 13 : R21 - R31
  • [2] Activating mutations in the ABCC8 gene in neonatal diabetes mellitus
    Babenko, Andrey P.
    Polak, Michel
    Cave, Helene
    Busiah, Kanetee
    Czernichow, Paul
    Scharfmann, Raphael
    Bryan, Joseph
    Aguilar-Bryan, Lydia
    Vaxillaire, Martine
    Froguel, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (05) : 456 - 466
  • [3] High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation
    Codner, E
    Flanagan, S
    Ellard, S
    García, H
    Hattersley, AT
    [J]. DIABETES CARE, 2005, 28 (03) : 758 - 759
  • [4] Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype
    Flanagan, SE
    Edghill, EL
    Gloyn, AL
    Ellard, S
    Hattersley, AT
    [J]. DIABETOLOGIA, 2006, 49 (06) : 1190 - 1197
  • [5] RETRACTED: Nicotinamide nucleotide transhydrogenase: A key role in insulin secretion (Retracted article. See vol. 19, pg. 344, 2014)
    Freeman, H
    Shimomura, K
    Horner, E
    Cox, RD
    Ashcroft, FM
    [J]. CELL METABOLISM, 2006, 3 (01) : 35 - 45
  • [6] Gloyn AL, 2004, NEW ENGL J MED, V351, P1470
  • [7] Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the β-cell potassium adenosine triphosphate channel
    Gloyn, AL
    Cummings, EA
    Edghill, EL
    Harries, LW
    Scott, R
    Costa, T
    Temple, IK
    Hattersley, AT
    Ellard, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08) : 3932 - 3935
  • [8] Relapsing diabetes can result from moderately activating mutations in KCNJ11
    Gloyn, AL
    Reimann, F
    Proks, P
    Pearson, ER
    Temple, IK
    Mackay, DJG
    Shield, JPH
    Freedenberg, D
    Noyes, K
    Ellard, S
    Ashcroft, FM
    Gribble, FM
    Hattersley, AT
    [J]. HUMAN MOLECULAR GENETICS, 2005, 14 (07) : 925 - 934
  • [9] Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes
    Gloyn, AL
    Pearson, ER
    Antcliff, JF
    Proks, P
    Bruining, GJ
    Slingerland, AS
    Howard, N
    Srinivasan, S
    Silva, JMCL
    Molnes, J
    Edghill, EL
    Frayling, TM
    Temple, IK
    Mackay, D
    Shield, JPH
    Sumnik, Z
    van Rhijn, A
    Wales, JKH
    Clark, P
    Gorman, S
    Aisenberg, J
    Ellard, S
    Njolstad, PR
    Ashcroft, FM
    Hattersley, AT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) : 1838 - 1849
  • [10] Activating mutations in Kir6.2 and neonatal diabetes - New clinical syndromes, new scientific insights, and new therapy
    Hattersley, AT
    Ashcroft, FM
    [J]. DIABETES, 2005, 54 (09) : 2503 - 2513